tdsRNA Therapy for Post-COVID Fatigue Symptom Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Post-COVID Conditions of fatigue, a subset of symptoms that persist even after SARS-COV-2 infection has resolved, significantly impact quality of life and are debilitating, with limited care options available, primarily relying on supportive care for potential spontaneous recovery.
Innovation Solution
Administration of a therapeutically effective amount of therapeutic double-stranded RNA (tdsRNA), specifically rIn·r(CxU)n or rugged dsRNA, to subjects who have recovered from SARS-COV-2 infection, to reduce or eliminate symptoms such as difficulty concentrating, inability to exercise, mental fatigue, and post-exertional malaise, even after the infection is no longer detectable.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If supportive care is provided for spontaneous recovery, then patient safety is maintained, but treatment effectiveness is insufficient and quality of life remains severely impacted
Solution Approach 1:
The patent changes the biochemical parameter by introducing therapeutically effective amounts of double-stranded RNA (dsRNA) that specifically target and inhibit SARS-CoV-2 replication mechanisms, transforming supportive care into targeted antiviral therapy that addresses the root cause of post-COVID fatigue symptoms
Solution Approach 2:
The dsRNA acts as an intermediary substance that mediates between the residual viral presence and the host immune system, modulating the immune response to reduce chronic inflammation and fatigue symptoms while maintaining safety
2Reliability
If no active treatment is administered, then treatment safety is maintained, but symptom duration increases and quality of life deteriorates
Solution Approach 1:
The treatment is administered after SARS-CoV-2 clearance is confirmed, acting preliminarily to prevent the establishment of chronic fatigue syndrome by interrupting the immune dysregulation process before it becomes entrenched, thereby reducing symptom duration
Solution Approach 2:
The dsRNA therapy provides continuous antiviral activity and immune modulation throughout the treatment course, maintaining useful action against residual viral mechanisms and immune dysregulation to accelerate symptom resolution
3Device complexity
If conventional supportive care is used, then treatment complexity is minimized, but cognitive function improvement is insufficient
Solution Approach 1:
The patent replaces the passive mechanical approach of supportive care with an active biochemical mechanism where dsRNA specifically inhibits viral replication and modulates immune responses, thereby improving cognitive function through targeted molecular action rather than general support
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of tdsRNA effectively reduces or eliminates PCC of fatigue symptoms within a few weeks to several months, improving cognitive functions and overall quality of life, with no severe adverse events reported in clinical trials.
Implementation Method 1
administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA)... to reduce or eliminate symptoms... within a few weeks to several months
Data Source
AI summary
Disclosed is a method for treating a subject that has previously been infected with SARS-COV-2 and exhibiting at least one Post COVID-19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.